Pharmabiz

SOFIE Biosciences doses first patient dosed in phase 3 trials of [18F]FAPI-74, a fluorine-18 labelled radiopharmaceutical targeting FAP for patients with GI cancers

SOFIE Biosciences doses first patient dosed in phase 3 trials of [18F]FAPI-74, a fluorine-18 labelled radiopharmaceutical targeting FAP for patients with GI cancers: Dulles, Virgi ...
Pharmabiz

Establishment Labs Holdings submits Motiva implants to US FDA for approval in primary and revision breast reconstruction

Establishment Labs Holdings submits Motiva implants to US FDA for approval in primary and revision breast reconstruction: Costa Rica Wednesday, December 31, 2025, 16:00 Hrs [IST] ...
Pharmabiz

Ultragenyx Pharma announces phase 3 Orbit & Cosmic results for setrusumab in osteogenesis imperfecta

Ultragenyx Pharma announces phase 3 Orbit & Cosmic results for setrusumab in osteogenesis imperfecta: Novato, California Wednesday, December 31, 2025, 18:00 Hrs [IST] Ultragenyx P ...
Pharmabiz

US FDA grants 510(k) clearance to StimLabs’ Theracor, a first human umbilical cord-derived medical device sheet

US FDA grants 510(k) clearance to StimLabs’ Theracor, a first human umbilical cord-derived medical device sheet: Roswell, Georgia Wednesday, December 31, 2025, 13:00 Hrs [IST] S ...
Pharmabiz

Enveric Biosciences receives US patent entitled, “Substituted Ethylamine Fused Heterocyclic Mescaline Derivatives”

Enveric Biosciences, a biotechnology company advancing novel neuroplastogenic small-molecule therapeutics to address psychiatric and neurological disorders, announced the issuance of US Patent No. 12, ...
Pharmabiz

WORK Medical’s subsidiary Hunan Saitumofei receives manufacturing approval for its Class II medical devices

WORK Medical’s subsidiary Hunan Saitumofei receives manufacturing approval for its Class II medical devices: Hangzhou, China Wednesday, December 31, 2025, 15:00 Hrs [IST] WORK M ...
Pharmabiz

Johnson & Johnson completes acquisition of clinical-stage biotechnology company, Halda Therapeutics

Johnson & Johnson completes acquisition of clinical-stage biotechnology company, Halda Therapeutics: New Brunswick, New Jersey Wednesday, December 31, 2025, 12:00 Hrs [IST] Johnso ...
Pharmabiz

Ministry of health issues draft amendment to remove cough syrups from Schedule K

Ministry of health issues draft amendment to remove cough syrups from Schedule K: Gireesh Babu, New Delhi Wednesday, December 31, 2025, 11:15 Hrs [IST] The Union health ministry h ...